

In The United States Patent and Trademark Office

In re application of:
Koenig, Scott et al.

Appl. No. **10/524,134**

Filed: **February 11, 2005**

For: **FcyRIIB-Specific Antibodies
and Methods of Use Thereof**

Art Unit: **1644**

Examiner: **Dahle, Chun Wu**

Atty. Docket: **1301.0012C**

Confirmation No.: **1503**

Amendment Pursuant to 37 C.F.R. §1.312

Filed via EFS-Web
Mail Stop Issue Fee
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

In response to the Notice of Inconsistency With Specification dated May 30, 2008,
Applicants submit this response. Kindly enter the amendment.

Amendments to the Specification: begin on page 2.

Amendments to the Claims: none.

Amendments to the Drawings: none

Applicants' Remarks: begin on page 16 of this submission.

No fee, other than those provided for on any accompanying Fee Transmittal Form are believed to be due in order for the timely consideration of this Reply. In the event that the Commissioner determines that an additional fee is required in for consideration of this submission, the U.S. Patent and Trademark Office is hereby authorized to charge any SMALL ENTITY fee deficiency, or credit any overpayment, to Deposit Account No. **05-0460** referencing Attorney Docket No. **1301.0012C**.